Cordis coronary stent patent infringement trial begins Feb. 9 in Delaware federal court.
This article was originally published in The Gray Sheet
Executive Summary
CORDIS SEEKING TO BLOCK SALES OF GUIDANT ACS Rx MULTI-LINK IN U.S., claiming the flexible design of the recently launched coronary stent infringes a key patent owned by Cordis parent Johnson & Johnson related to the Palmaz-Schatz and Crown coronary stent systems.